Goyal, Gaurav http://orcid.org/0000-0001-6148-5177
Rajkumar, S. Vincent
Lacy, Martha Q.
Gertz, Morie A.
Buadi, Francis K.
Dispenzieri, Angela
Hwa, Yi L.
Fonder, Amie L.
Hobbs, Miriam A.
Hayman, Suzanne R.
Zeldenrust, Steven R.
Lust, John A.
Russell, Stephen J.
Leung, Nelson http://orcid.org/0000-0002-5651-1411
Kapoor, Prashant
Go, Ronald S. http://orcid.org/0000-0002-8284-3495
Gonsalves, Wilson I.
Kourelis, Taxiarchis V.
Warsame, Rahma
Kyle, Robert A.
Kumar, Shaji K. http://orcid.org/0000-0001-5392-9284
Article History
Received: 27 November 2018
Revised: 31 January 2019
Accepted: 7 February 2019
First Online: 20 February 2019
Compliance with ethical standards
:
: MAG reports personal fees from Ionis/Akcea, Alnylam, Prothena, Celgene, Janssen, grants and personal fees from Spectrum, personal fees from Annexon, Appellis, Amgen, Medscape, Physicians Education Resource, personal fees for Data Safety Monitoring board from Abbvie, personal fees from Research to Practice, speaker fees from Teva, Speaker fees from Johnson and Johnson; Speaker fees from Medscape, Speaker fees DAVA oncology; Advisory Board for Pharmacyclics Advisory Board for Proclara outside the submitted work; Royalties from Springer Publishing Grant Funding Amyloidosis Foundation; grant from International Waldenstrom FoundationNCI SPORE MM SPORE 5P50 CA186781-04. SKK received consultancy from Celgene, Millennium, Onyx, Janssen, and BMS and research funding from Celgene, Millennium, Novartis, Onyx, AbbVie, Janssen, and BMS. MQL received research funding from Celgene. DD received research funding from Karyopharm Therapeutics, Amgen, and Millennium Pharmaceuticals. PK received research funding from Takeda, Sanofi, Janssen, Glaxo Smith Kline and Amgen. AD received research funding from Jannsen, Takeda, Celgene, Pfizer, Alnylam, Prothena, and GSK, and serves on the advisory board of Takeda and Intellia. NL serves on the advisory board of Takeda and Prothena. The remaining authors declare that they have no conflict of interest.